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A 58-residue peptide has been isolated from extracts of porcine brain and shown to be an N-terminally 
extended cholecystokinin (CCK). The amino acid sequence of this peptide is: Ala-Val-Gln-Lys-Val-Asp- 
Gly-Glu-Ser-Arg-Ala-His-Leu-Gly-Ala-Leu-Leu-Ala-Arg-Tyr-Ile-Gln-Gln-Ala-Arg-Lys-Ala-Pro-Ser-Gly- 
Arg-Val-Ser-Met-Ile-Lys-Asn-Leu-Gln-Ser-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser-Asp-Arg-Asp-Tyr(SO~)-Met- 
Gly-Trp-Met-Asp-Phe-NH2. The peptide was found to induce contraction of the guinea-pig gallbladder, but 
the pattern of this action seemed to differ from those of CCK-8 and CCK-33. 
Brain peptide Gut peptide Brain CCK CCK-58 Amino acid sequence C-terminal amide 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Cholecystokinin (CCK), originally isolated in [l] 
from porcine intestine as a 33-residue peptide, has 
been shown to display various biological effects 
including stimulation of both pancreatic exocrine 
secretion and gallbladder contraction [2]. Later, its 
larger molecular forms, CCK-39 [3] and CCK-58 
[4], were isolated from porcine and canine intes- 
tine, respectively. CCK-like immunoreactivity has 
been found to occur not only in the intestine but 
also in the brain [5,6]. Subsequently, an 8-residue 
peptide has been isolated from sheep brain and 
shown to be identical to the C-terminal octapeptide 
of CCK-33 [7]. We have reported that porcine 
brain contains substantial amounts of a CCK 
molecule with 58 amino acid residues [8,9]. This 
paper describes the isolation and complete amino 
acid sequence of this brain peptide. 
Preliminary communications on this study have been 
published; Tatemoto, K., First International Meeting of 
Interdisciplinary Neuroendocrinology, June 1983, Graz, 
Austria; Tatemoto, K., Shizuoka Symposium on Brain- 
Gut Peptides, July 1983, Shizuoka, Japan 
Thermolysin was obtained from Daiwa Kasei 
K.K., Osaka, and trypsin (L-1-tosylamide-2- 
phenylethyl chloromethyl ketone-treated) from 
Worthington. CCK-58 was assayed by the biologi- 
cal method using contraction of the guinea-pig 
gallbladder in vivo [lo] and by the chemical 
method based on the detection of C-terminal amide 
(phenylalanine amide) released by treatment of 
samples with thermolysin [ 111. High-performance 
liquid chromatography (HPLC) was performed in 
a Waters instrument using reversed-phase p Bonda- 
pak cl8 columns under chromatographic condi- 
tions described in the legends to fig.l-3. N-termi- 
nal amino acids were determined by the dansyl 
method [ 121. Amino acid analyses were preformed 
with a Beckman 121 M amino acid analyser after 
hydrolysis of samples in 5.7 M HCl containing 
0.5% phenol at 110°C for 24 h. The tryptophan 
content was determined after hydrolysis in 3 M 
mercaptoethanesulfonic acid [ 131. Step-wise se- 
quencer degradation of the intact peptide was car- 
ried out in a Beckman 890 D liquid-phase sequencer 
in the presence of glycine-precycled polybrene [ 141. 
Phenylthiohydantoin derivatives were identified by 
HPLC [15]. 
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3. RESULTS 
3. I. Isolation procedures 
Porcine brain (1000 kg) was boiled (10 min), 
frozen, and extracted at 4-5°C with 0.5 M acetic 
acid (20001) overnight without stirring and then 
for 5-6 h with stirring. After filtration, the pep- 
tides in the extract were adsorbed onto alginic acid 
(30 kg wet wt) at pH2.7, eluted with 0.2M HCl, 
precipitated by NaCl at salt saturation and col- 
lected by filtration. The peptide precipitate (970g 
wet wt), containing the CCK-like bioactivity 
(0.2 CCK units/mg), was dissolved in water (10 1) 
and peptides in the solution were re-precipitated by 
NaCl at pH 4.0 and collected by filtration. This 
second precipitate (800 g wet wt) was suspended in 
methanol (40 1) containing 0.05% mercaptoethanol 
and extracted for 10min with vigorous stirring. 
After filtration, the methanol-insoluble material 
was dried under vacuum overnight. The dried 
material (254g, 0.7 CCK units/mg) was dissolved 
in water (2.5 1) and the pH of the solution was ad- 
justed to 7.2. After removal by centrifugation of 
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Fig.1. HPLC profile of the CCK fraction from CM- 
cellulose chromatography. An aliquot (10mg) of the 
fraction (121 mg) was applied to a reversed-phase,eBon- 
dapak Cl8 column (7.8 x 300 mm) and eluted at a flow 
rate of 2ml/min with 40% ethanol containing 5 mM 
ammonium acetate and 0.2% acetic acid. The fraction 
containing CCK (hatched area) was detected by using 
Fig.2. HPLC profile of the CCK fraction (fig.1). The 
CCK-containing fraction (a total of 300 ml) was concen- 
trated under vacuum to half the volume to remove the 
ethanol. An aliquot (50 ml) of the solution (150 ml) was 
then applied to a reversed-phasepBondapak Crs column 
(7.8 x 300 mm) for the second time through the solvent 
delivery system at a flow rate of 2ml/min. The HPLC 
column was then washed with 40 ml of 25% acetonitrile 
containing 0.1% trifluoroacetic acid at the same flow 
rate. The peptides, concentrated on the HPLC column, 
were eluted at a flow rate of 2ml/min with a linear 
gradient system (90min) from 25% to 40% acetonitrile 
containing 0.1% trifluoroacetic acid. The major peak 
(hatched area) contained CCK and this peak fraction 
was subjected to structural and biological studies after 
both the biological and chemical assay methods. lyophilization. 
the precipitate formed, 2~01s of ethanol were 
added to the supernatant and this ethanol precipi- 
tate was collected by suction filtration. This pre- 
cipitate was suspended in water (5 1) and the pH of 
the suspension was slowly adjusted to 4.2 by addi- 
tion of acetic acid under constant stirring. The in- 
soluble material was removed by centrifugation 
and the supernatant was lyophilized. The lyophi- 
lized material (49.5 g, 2.0CCK units/mg) was 
chromatographed on Sephadex G-25 (fine) in 
0.2M acetic acid. The fractions containing the 
CCK-like activity were pooled and lyophilized. 
These fractions (a total of 15.4 g) were further puri- 
fied by ion exchange chromatography on CM-cel- 
lulose with a step-wise elution by 0.04, 0.1 and 
0.2 M ammonium bicarbonate. The CCK fraction, 
eluted at 0.1 M ammonium bicarbonate, was lyo- 
philized and the lyophilized material (554 mg) was 
chromatographed on Sephadex G-50 (fine) in 
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0.2 M acetic acid containing 0.02% ethylmercap- 
tan. The major peak in the chromatogram con- 
tained the CCK activity and this fraction was lyo- 
philized. An aliquot (121 mg) of the lyophilized 
fraction (206 mg) was then subjected to successive 
HPLC on a reversed-phase PBondapak Cis col- 
umn. Fig. 1 illustrates a typical HPLC elution pro- 
file of the CCK fraction in 40% ethanol containing 
5 mM ammonium acetate and 0.2% acetic acid 
under isocratic conditions. The CCK-containing 
fraction was detected by both the biological and 
the chemical methods, and was concentrated under 
vacuum to remove the ethanol. An aliquot (50 ml) 
of the concentrated solution (total, 150 ml) was 
applied to the HPLC column using the solvent de- 
livery system and the HPLC column was washed 
with 25% acetonitrile containing 0.1% trifluoro- 
acetic acid. The peptides were eluted from the col- 
umn with increasing concentration of acetonitrile 
using a linear gradient system (fig.2). The major 
peak in the HPLC chromatogram contained a 
CCK-like peptide, measured by the assay methods, 
and the fraction containing this peak was lyophi- 
lized. It was noted that this CCK-like peptide was 
eluted in more hydrophobic HPLC solvent systems 
than that for CCK-8, CCK-33 or CCK-39. The 
lyophilized preparation (total, 1 .O mg) was found 
to be homogeneous and was subjected to structural 
analysis. 
3.2. Structural analysis 
The results of amino acid analysis indicated that 
the brain peptide consisted of 58 residues: Alas- 
Args-ASX6-GlXs-Gly4-Hisz-Ile3-Leu5-Lyss-Mets- 
Phel-Proz-Serb-Trpi-Tyrz-Vals, as reported [9]. 
The N-terminal amino acid of the peptide was 
found to be alanine. The results of C-terminal 
amide determination [ll] indicated that the brain 
peptide, like other CCK molecules, has a C-termi- 
nal phenylalanine amide. Treatment of the peptide 
with trypsin yielded a total of nine fragments 
which were separated by HPLC, as shown in fig.3. 
When the elution volumes in the HPLC of these 
fragments were compared with those of tryptic 
fragments of CCK-39, it was found that 6 of the 9 
fragments were eluted in identical positions to the 
corresponding fragments of CCK-39. Moreover, 
these 6 fragments were identical in amino acid 
composition to the corresponding fragments of 
C’CK-39. These results indicate that the brain pep- 
tide may be an N-terminally extended form of 
CCK-39. The C-terminal tryptic fragment (T-9) of 
the brain peptide had an amino acid composition, 
terminal structure and biological activity identical 
to the octapeptide CCK-8. Edman degradation of 
the intact peptide in a Beckman 890 D liquid-phase 
sequencer yielded the amino acid sequence up to 
residue 57, establishing the brain peptide to be 
a CCK with 58 amino acid residues. The tyrosine 
O-sulfate residue at position 52 of the brain pep- 
tide was identified as a phenylthiohydantoin tyro- 
sine in the sequencer analysis, probably due to loss 
of the sulfate group during the repetitive degrada- 
tion procedures. However, since the C-terminal 
tryptic fragment of the brain CCK was eluted in 
the HPLC at an identical volume to CCK-8 and 
was highly biologically active, the residue at posi- 
tion 52 should be a tyrosine O-sulfate. The repeti- 
tive yield of the sequence analysis was 94-95%. 
From the results of amino acid analysis, C-termi- 
nal determination and sequence analysis, the com- 
plete amino acid sequence of brain CCK-58 was 
deduced to be as in fig.4. 
ELUTION VOLUME (ml) 
Fig.3. HPLC separation of tryptic fragments (T-l-T-9) 
of brain CCK-58. CCK-58 (60pg) was dissolved in 30~1 
of 1% N&HCOs and 1~1 trypsin solution (2 mg/ml) 
was added. After incubation at room temperature for 
18 h, boiling for 6 min, and lyophilization, the tryptic 
peptides were separated on a reversed-phase HPLC 
column (PBondapak Ci8, 3.9 x 3OOmm, Waters) with a 
linear gradient of 0.12% trifluoroacetic acid/water and 
0.1 Vo trifluoroacetic acid/acetonitrile ata flow rate of 
1 ml/min. The dashed line indicates the gradient profile. 
The tryptic fragments (T-4-T-9), shown in the black 
peaks, are identical to tryptic fragments of CCK-39. 
291 
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1 5 10 15 
ALA-VAL-GLN-LYS-VAL-ASP-GLY-GLU-SER-ARG-ALA-HIS-LEU-GLY-ALA-LEU-LEU-ALA-ARG- 
-T-l - M T-2 WI T-3 
(28)(31) (26) (11) (10) (10) (10) (9) (9) 
20 25 30 35 
TYR-ILE-GLN-GLN-ALA-ARG-LYS-ALA-PRO-SER-GLY-ARG-VAL-SER-MET-ILE-LYS-ASN-LEU- 
4 T-4 *d T-5 . -T-6 - c--- 
(10) (10) (7) (7) (6) (5) (4) 
40 45 50 55 
GLN-SER-LEU-ASP-PRO-SER-HIS-ARG-ILE-SER-ASP-ARG-ASP-TYR-UET-GLY-TRP-MET-ASP-P"E-NH* 
T-7 w 
i2,_ 
T-8 - * T-9 * 
(3) (1) 
Fig.4. The complete amino acid sequence of CCK-58 (porcine brain). T-l to T-9 are tryptic fragments. Figures in parentheses denote 
nmoles of stabie phenylthiohydantoin amino acids recovered from sequencer degradation. Ty: indicates tyrosine O-sulfate. 
4. DISCUSSION 
Fig.5 shows a comparison of the primary struc- 
tures of porcine CCK-58 with other known CCK 
molecules. A high degree of sequence homology 
exists between porcine brain and canine intestinal 
CCK-58. However, there are differences, particu- 
larly at the N-terminal region (position l-9). The 
structural differences may be due to species varia- 
tions. 
Recently, authors in [16] have isolated CCK-8 
and N-terminal fragments of CCK-33, CCK-39 and 
CCK-58 from porcine brain. They reported that 
the fragments, CCK-33 desnonapeptide, CCK-39 
desnonapeptide and desdecapeptide, and CCK-58 
desnonapeptide, were about equally prominent, 
but, no intact molecule of CCK-33, CCK-39 or 
CCK-58 was detected in the brain [16]. The present 
study, however, clearly shows the occurrence of 
substantial amounts of intact CCK-58. The results 
of the biological and the chemical assays suggest 
that CCK-58, but not CCK-33 and CCK-39, is 
present as one of the major CCK forms in the 
brain. Here, the brains were boiled prior to the ex- 
traction in order to inactivate proteolytic enzymes 
in the tissue. Since this precaution was not taken in 
1 10 20 30 40 50 
l 
brain CCK-58 
(prcim) 
~V~KVDGESRAHLGALlARVlQQARKAPS6RVSUIKNlQSLDPSHRlSORDV~G"M~Fo -- _________________________________________________ 
intestinal CCK-33 KAPSGRVSMIKNLq~C~P~~~~~~~~~~~~~~~" __---mm----em 
(Porcin) 
. 
brain CCK-8 
(sheep md porcine) 
OVMGNMDF" -------- 
Fig.5. Comparison of the primary structures of CCK-58 (porcine brain) and known CCKs. Identities are underlined. ;, tyrosine 
O-sulfate. F”, phenylalanine amide. 
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[16], it is possible that CCK-58 might have 
degradated to CCK-8 and the N-terminal 
ments during the extraction procedures. 
been 
frag- 
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CCK-58 (porcine brain) contracts the smooth 
muscle of the guinea-pig gallbladder. But, the pat- 
tern of the action seems to be different from those 
of CCK-8, CCK-33 and CCK-39: CCK-58 had a 
slower onset and prolonged duration as compared 
with the patterns of the gallbladder contraction 
elicited by other CCKs. A recent study indicated 
that CCK-58 selectively increased dopamine turn- 
over in certain CCK-positive dopamine nerve ter- 
minals in which other known CCK molecules did 
not (Fuxe et al., personal communication). It may 
therefore be speculated that CCK-58 has different 
biological roles from those of other known CCK 
molecules. 
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